Toward understanding and exploiting tumor heterogeneity

Nature Medicine

Volumn 21, Issue 8, 2015, Pages 846-853

  Alizadeh, Ash A ^a   Aranda, Victoria ^a   Bardelli, Alberto ^b   Blanpain, Cedric ^c   Bock, Christoph ^d   Borowski, Christine ^e   Caldas, Carlos ^f   Califano, Andrea ^g   Doherty, Michael ^h,r   Elsner, Markus ^i,s   Esteller, Manel ^j,t   Fitzgerald, Rebecca ^j,u   Korbel, Jan O ^j,v   Lichter, Peter ^k,w   Mason, Christopher E ^l,x   Navin, Nicholas ^m,s   Pe'Er, Dana ⁿ   Polyak, Kornelia ^o   Roberts, Charles W M ^p   Siu, Lillian ^q   Snyder, Alexandra ^r   Stower, Hannah ^c,j   Swanton, Charles ^j   Verhaak, Roel G W ^r   Zenklusen, Jean C ^y   Zuber, Johannes ^z   Zucman Rossi, Jessica ^aa   more..

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c Nature Medicine   (United States)

^d UNIVERSITY OF TURIN   (Italy)

^e CANDIOLO CANCER INSTITUTE   (Italy)

^f UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^g ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j Och Spine at New York Presbyterian Hospitals   (United States)

^k GENENTECH INC   (United States)

^l Nature Biotechnology   (United States)

^m BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

ⁿ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^o EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^p GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^q WEILL CORNELL MEDICAL COLLEGE   (United States)

^r UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^s HARVARD MEDICAL SCHOOL   (United States)

^t PRINCESS MARGARET HOSPITAL   (Canada)

^u MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^v UNIVERSITY COLLEGE LONDON   (United Kingdom)

^w UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^x THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^y NATIONAL CANCER INSTITUTE   (United States)

^z RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^aa INSERM   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; PROTEIN;

CANCER GENETICS; CANCER IMMUNOLOGY; CANCER RESEARCH; CELL HETEROGENEITY; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DNA SEQUENCE; ENVIRONMENTAL FACTOR; EPIGENETICS; GENOME; HUMAN; IMMUNOGENICITY; MINIMALLY INVASIVE PROCEDURE; NON INVASIVE PROCEDURE; NONHUMAN; PATIENT ADVOCACY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TRANSLATIONAL RESEARCH; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR MODEL; GENETICS; HIGH THROUGHPUT SEQUENCING; NEOPLASMS; PATHOLOGY; QUALITY CONTROL;

BENCHMARKING; EPIGENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84938799837     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3915     Document Type: Review

References (36)

1. Zardavas, D. et al. Clinical management of breast cancer heterogeneity. Nat. Rev. Clin. Oncol. 12, 381-394 (2015).
2. Marusyk, A. et al. Intra-tumour heterogeneity: a looking glass for cancer? Nat. Rev. Cancer 12, 323-334 (2012).
3. McGranahan, N. &Charles Swanton, C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27, 15-26 (2015).
4. Chen, J.C. et al. Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks. Cell 159, 402-414 (2014).
5. Gould, S.E., Junttila, M.R. &de Sauvage, F.J. Translational value of mouse models in oncology drug development. Nat. Med. 21, 431-439 (2015).
6. Li, S. et al. Dynamic evolution of clonal epialleles revealed by methclone. Genome Biol. 15, 472 (2014).
7. de Biasi, A.R., Villena-Vargas, J. &Adusumilli, P.S. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin. Cancer Res. 20, 5384-5391 (2014).
8. Postow, M.A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925-931 (2012).
9. Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373-377 (2015).
10. Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6, 26ra32 (2014).
11. Andtbacka, R.H.I. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. doi:10.1200/JCO.2014.58.3377 (26 May 2015).
12. Eggermont, A.M. et al. Cancer Core Europe: a consortium to address the cancer care-cancer research continuum challenge. Eur. J. Cancer 50, 2745-2746 (2014).
13. Bansal, M. et al. A community computational challenge to predict the activity of pairs of compounds. Nat. Biotechnol. 32, 1213-1222 (2014).
14. Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. doi:10.1038/nm.3870 (1 June 2015).
15. Thress, K.S. et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21, 560-562 (2015).
16. Newman, A.M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20, 548-554 (2014).
17. Dawson, S.J. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199-1209 (2013).
18. Rodrigues, T.B. et al. Magnetic resonance imaging of tumor glycolysis using hyperpolarized 13C-labeled glucose. Nat. Med. 20, 93-97 (2014).
19. Newman, A.M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453-457 (2015).
20. Gentles, A.J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 940-947 (2015).
21. Pan, X. et al. Proc. Natl. Acad. Sci. USA 110, 594-599 (2013).
22. Macosko, E.Z. et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 161, 1202-1214 (2015).
23. Klein, A.M. et al. Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. Cell 161, 1187-1201 (2015).
24. Fan, H.C., Fu, G.K. &Fodor, S.P. Expression profiling. Combinatorial labeling of single cells for gene expression cytometry. Science 347, 910-914 (2015).
25. Murphy, P.J. et al. Single-molecule analysis of combinatorial epigenomic states in normal and tumor cells. Proc. Natl. Acad. Sci. USA 110, 7772-7777 (2013).
26. Li, S. et al. The pivotal regulatory landscape of RNA modifications. Annu. Rev. Genomics. Hum. Genet. 15, 127-150 (2014).
27. Dey, S.S. et al. Integrated genome and transcriptome sequencing of the same cell. Nat. Biotechnol. 33, 285-289 (2015).
28. Seligson, D.B. et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435, 1262-1266 (2005).
29. Gomez, D. et al. Detection of histone modifications at specific gene loci in single cells in histological sections. Nat. Methods 10, 171-177 (2013).
30. Giesen, C. et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat. Methods 11, 417-422 (2014).
31. Angelo, M. et al. Multiplexed ion beam imaging of human breast tumors. Nat. Med. 20, 436-442 (2014).
32. Lee, J.H. et al. Fluorescent in situ sequencing (FISSEQ) of RNA for gene expression profiling in intact cells and tissues. Nat. Protoc. 10, 442-458 (2015).
33. Chen, K.H., Boettiger, A.N., Moffitt, J.R., Wang, S. &Zhuang, X. Spatially resolved, highly multiplexed RNA profiling in single cells. Science 348, 6233 (2015).
34. Lee, J.H. et al. Highly multiplexed subcellular RNA sequencing in situ. Science 343, 1360-1363 (2014).
35. O'Connor, J.P. et al. Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin. Cancer Res. 21, 249-257 (2015).
36. Haeno, H. et al. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 148, 362-375 (2012).